📊 PDEX Key Takeaways
Is Pro Dex Inc. (PDEX) a Good Investment?
Pro Dex demonstrates robust fundamental health with 23.7% revenue growth, exceptional operating margins (17.1%), and strong free cash flow generation (5.7M). The company maintains a conservative balance sheet with 0.37x debt-to-equity, excellent liquidity (4.03x current ratio), and efficient operations requiring minimal capital expenditure.
Why Buy Pro Dex Inc. Stock? PDEX Key Strengths
- Strong revenue growth (23.7% YoY) with excellent profitability metrics (17.1% operating margin, 18.5% net margin)
- Exceptional cash generation with 5.7M free cash flow (15.4% FCF margin) requiring only 168K in capex
- Fortress balance sheet with 0.37x debt-to-equity, 4.03x current ratio, and 18.7x interest coverage ratio
- Solid returns on capital (ROE 16.5%, ROA 11.0%) demonstrating efficient asset utilization
PDEX Stock Risks: Pro Dex Inc. Investment Risks
- Extremely high net income growth (5692% YoY) indicates prior year was unprofitable or near-breakeven, raising sustainability questions
- Limited cash position (5.3M) relative to long-term debt (15.4M) constrains financial flexibility
- Medical device sector faces intense competition, regulatory complexity, and customer concentration risk
Key Metrics to Watch
- Operating margin sustainability at 17.1% level in coming quarters
- Revenue growth trajectory and gross margin stability
- Free cash flow consistency and capital allocation efficiency
Pro Dex Inc. (PDEX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.03x current ratio provides a solid financial cushion.
PDEX Profit Margin, ROE & Profitability Analysis
PDEX vs Healthcare Sector: How Pro Dex Inc. Compares
How Pro Dex Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Pro Dex Inc. Stock Overvalued? PDEX Valuation Analysis 2026
Based on fundamental analysis, Pro Dex Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Pro Dex Inc. Balance Sheet: PDEX Debt, Cash & Liquidity
PDEX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Pro Dex Inc.'s revenue has grown significantly by 75% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.60 reflects profitable operations.
PDEX Revenue Growth, EPS Growth & YoY Performance
PDEX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $16.8M | $2.0M | $0.61 |
| Q1 2026 | $14.9M | $2.5M | $0.75 |
| Q3 2025 | $14.3M | $540.0K | $0.15 |
| Q2 2025 | $12.6M | -$115.0K | $-0.03 |
| Q1 2025 | $11.9M | -$615.0K | $-0.17 |
| Q3 2024 | $13.1M | $540.0K | $0.15 |
| Q2 2024 | $11.3M | -$115.0K | $-0.03 |
| Q1 2024 | $11.1M | -$615.0K | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Pro Dex Inc. Dividends, Buybacks & Capital Allocation
PDEX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Pro Dex Inc. (CIK: 0000788920)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PDEX
What is the AI rating for PDEX?
Pro Dex Inc. (PDEX) has an AI rating of BUY with 73% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PDEX's key strengths?
Claude: Strong revenue growth (23.7% YoY) with excellent profitability metrics (17.1% operating margin, 18.5% net margin). Exceptional cash generation with 5.7M free cash flow (15.4% FCF margin) requiring only 168K in capex.
What are the risks of investing in PDEX?
Claude: Extremely high net income growth (5692% YoY) indicates prior year was unprofitable or near-breakeven, raising sustainability questions. Limited cash position (5.3M) relative to long-term debt (15.4M) constrains financial flexibility.
What is PDEX's revenue and growth?
Pro Dex Inc. reported revenue of $37.2M.
Does PDEX pay dividends?
Pro Dex Inc. does not currently pay dividends.
Where can I find PDEX SEC filings?
Official SEC filings for Pro Dex Inc. (CIK: 0000788920) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PDEX's EPS?
Pro Dex Inc. has a diluted EPS of $2.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PDEX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Pro Dex Inc. has a BUY rating with 73% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is PDEX stock overvalued or undervalued?
Valuation metrics for PDEX: ROE of 16.5% (sector avg: 15%), net margin of 18.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy PDEX stock in 2026?
Our dual AI analysis gives Pro Dex Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is PDEX's free cash flow?
Pro Dex Inc.'s operating cash flow is $5.9M, with capital expenditures of $168.0K. FCF margin is 15.4%.
How does PDEX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.5% (avg: 12%), ROE 16.5% (avg: 15%), current ratio 4.03 (avg: 2).